Back to search results

Observational Study for Solid Tumor Tissue Collection

This study is collecting tissue samples from people who are already having a biopsy or surgery for certain types of cancer at the NIH Clinical Center. The goal is to find new ways to treat tumors by studying these samples. This is an observational study, meaning you won't receive any new treatments as part of the study. You can join if you are 2 years or older and have a precancerous (a condition that might become cancer) or cancerous solid tumor. The study aims to collect samples to identify new targets for future cancer therapies.

Study design
This is an observational study with a planned enrollment of 1800 participants. It is not testing any specific intervention.
What's involved
You would provide tissue samples during a clinically indicated surgical procedure or biopsy you are already scheduled to have.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint for sample collection is measured at 2 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT01915225

Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer

Recruiting
Not specifiedAges 2+Observational
National Cancer Institute (NCI)
~1,800 participants
Updated 2026-08-24 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Collection of biologic samples from participants undergoing diagnostic or therapeutic interventions for premalignant, primary or metastatic solid tumors for the purpose of identifying novel molecular and biologic therapeutic targets
Measured over 2 month

Conditions

Colorectal Neoplasms
Gastric Neoplasms
Cholangiocarcinoma
Bile Duct Cancer
Pancreas Cancer

Explore related trials

Bile Duct CarcinomaCholangiocarcinomaColorectal CarcinomaGastric CarcinomaPancreatic CarcinomaSolid Neoplasm

Where it's being run

1 sites across 1 states
Maryland1

Study leadership

  • Jonathan M Hernandez, M.D. · PRINCIPAL_INVESTIGATOR · National Cancer Institute (NCI)

Who to contact

Cathleen E Hannah, C.R.N.P.
[email protected]
(240) 858-7006
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants must be 2 years of age or older. Note: Participants greater than or equal to 2 and \< 18 years of age may only participate in research sample collection if the tissue acquisition is performed during a clinically indicated surgical procedure, and the biospecimen sampling (e.g., blood, urine, ascites, bile, or \[clinically indicated\] resected tumor tissue) does not add risk to the clinically indicated procedures.
Participants who have premalignant, primary, or metastatic solid tumors based upon either radiographic or clinical suspicion, biochemical testing, a genetic predisposition, or histological/cytological analysis that requires surgery or biopsy as part of the diagnosis, prevention, treatment, and/or follow-up.
Participants without solid tumors in whom a diagnostic, preventative, or therapeutic intervention is being performed, but for whom surgical quality and safety outcomes data are generated.
Participants should have laboratory and physical examination parameters within acceptable limits prior to biopsy or surgery.
Participants must be planning to undergo surgery or biopsy as part of their normal treatment plan.
Ability of participant, parent/guardian or legally authorized representative (LAR) to understand and the willingness to sign a written informed consent document.

What this trial measures

  • Collection of biologic samples from participants undergoing diagnostic or therapeutic interventions for premalignant, primary or metastatic solid tumors for the purpose of identifying novel molecular and biologic therapeutic targets2 month

    Identification of novel molecular and biologic therapeutic targets